Palner M
Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mpalner@health.sdu.dk.
ArticlePsilocybin
Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks.
PreprintPsilocybin
Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic Review
PreprintPsilocybin
Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.
ArticlePsilocybin
Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins.
ArticleDMT
N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain.
ArticlePsilocybin
Beyond the 5-HT<sub>2A</sub> Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
ArticleDMT
A pilot study of cerebral metabolism and serotonin 5-HT<sub>2A</sub> receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.
ArticlePsilocybin
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.
ArticlePsychedelics
Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene Egr3.
ArticlePsilocybin